Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: A case-control postmarketing surveillance study

Retina

Volumn 30, Issue 2, 2010, Pages 271-274

  French, Dustin D ^a   Margo, Curtis E ^b  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Case control study; Central serous chorioretinopathy; Drug surveillance study; Drug related side effect; Phosphodiesterase inhibitors; Sildenafil

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CENTRAL SEROUS RETINOPATHY; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETINA MACULOPATHY; RISK ASSESSMENT; VETERAN;

ADOLESCENT; ADULT; CARBOLINES; CASE-CONTROL STUDIES; CENTRAL SEROUS CHORIORETINOPATHY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; PURINES; SULFONES; TRIAZINES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; YOUNG ADULT;

EID: 76749138490     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b7740f     Document Type: Article

References (11)

1. Bird AC. Pathogenesis of serous detachment of retina and pigment epithelium. In: Ryan SJ, ed. Retina. Vol.3. St. Louis, MO: CV Mosby Company; 2001:995-1002.
2. Gass JDM. Stereoscopic Atlas of Macular Disease. 4th ed. St. Louis, MO: CV Mosby Company; 1997:52-70.
3. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47:431-448.
4. Fawzi AA, Holland GN, Kreiger AE, Heckenlively JR, Arroyo JG, Cunningham ET Jr. Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 2006;113:805-813.
5. Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina 2008;28:606-609.
6. French DD, Margo CE, Campbell RR. Prevalence of phosphdiesterase-5 inhibitor use in the VHA is 2004 and 2005 is twice that of a commercial health plan in 2001. J Manag Care Pharm 2006;12:692-693.
7. Margo CE, French DD. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthalmol 2007;143:538-539.
8. French DD, Margo CE. Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosophodiesterase-5 inhibitors with organic nitrates or--blockers. Drug Saf 2008;31:241-247.
9. Hulley SB, Cummings SR, eds. Designing Clinical Research. Baltimore, MD: Williams & Wilkins; 1998:219.
10. Klein ML, van Buskirk EM, Friedman E, Gragoudas E, Chandra S. Experience with nontreatment of central serous choroidopathy. Arch Opthhalmol 1974;91:247-250.
11. Guyere DR, Gragoudas ES. Central serous chorioretinopathy. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol.2. Philadelphia, PA: WB Saunders; 1994:818.